Navigation Links
Marken Meets Critical Demand For In Vitro Lab Shipments
Date:5/7/2013

RESEARCH TRIANGLE PARK, N.C., May 7, 2013 /PRNewswire/ -- Marken is experiencing significant growth in demand for their specialized handling and shipments of biopsied embryo cells to laboratories across the US.  These cells are often used in Pre-Implantation Genetic Diagnostic Testing (PGD) and to diagnose certain diseases and conditions during in vitro fertilization (IVF) treatments.  Marken is well known for its highly personalized service which requires that the samples are placed in customized, temperature controlled containers and rapidly transported to specialized laboratories, where they are tested, often within 24 hours.  With time being such a critical element, the demand for Marken's logistical services continues to grow with the increased demand for IVF and PGD services.

(Logo: http://photos.prnewswire.com/prnh/20110930/NY78064LOGO)

Marken is 100% dedicated to the life sciences industry, which makes them uniquely qualified to work with IVF clinics and PGD laboratories, universities and research centers that provide these services to patients.

Wes Wheeler , Marken's Chief Executive Officer, believes more and more laboratories are turning to Marken for this type of specialized service. He commented, "We do whatever it takes to deliver these irreplaceable samples under any circumstances.  The coordination and dedication between our local Marken staff and their laboratory customers is both impressive and heartwarming. The samples may arrive anytime during the day or night and our teams will stay until the last sample is delivered. We understand our role in delivering to the laboratories as quickly and as safely as possible. It's a powerful mission."

IVF can be a complex and expensive procedure, increasing the critical nature of selecting a specialized courier who can guarantee on-time delivery and careful handling of their samples.  An international committee estimates that the total number of IVF births has reached five million worldwide. With such a longstanding history in the pharma industry, Marken is poised to continue to lead and grow the challenging dynamics of supplying logistics to the market for Assisted Reproductive Technologies.

About Marken
Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment naive geographies.

www.marken.com


'/>"/>
SOURCE Marken
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Marken Launches Exclusive Shipping System for Specimen Logistics
2. Marken Opens Two Pharmaceutical Depots In New York & Germany
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients
5. When nerve meets muscle, biglycan seals the deal
6. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
7. Human Genome Decoder and Artificial Life Creator, J. Craig Venter to Speak at "The Atlantic Meets the Pacific"
8. Veridiams Training Program Wins Accolades and Awards- Meets Skilled Labor Challenge Head On
9. Origami meets chemistry in scholarly video-article
10. SPIE ‘gold’ open access program meets new needs of UK authors -- and others
11. Berkeley Lab seeks to help US assert scientific leadership in critical materials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
Breaking Biology News(10 mins):